ConductScience.org, home
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
API referenceFor AI assistants

Trial · NCT03036813

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 18 of 18

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24Voxelotor 900 mg30Participants
Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24Voxelotor 1500 mg46Participants
Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24Placebo6Participants
Annualized Vaso-Occlusive Crisis (VOC) Incidence RateVoxelotor 900 mg2.495% Confidence Interval 1.9 to 3.1Events per year
Annualized Vaso-Occlusive Crisis (VOC) Incidence RateVoxelotor 1500 mg2.495% Confidence Interval 1.8 to 3.1Events per year
Annualized Vaso-Occlusive Crisis (VOC) Incidence RatePlacebo2.895% Confidence Interval 2.2 to 3.6Events per year
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 900 mg-20.1Standard Error 3.41percentage change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 1500 mg-29.1Standard Error 3.46percentage change
Percentage Change From Baseline in Hemolysis MeasuresPlacebo-2.8Standard Error 3.51percentage change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 900 mg4.7Standard Error 5.13percentage change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 1500 mg-6.4Standard Error 5.17percentage change
Percentage Change From Baseline in Hemolysis MeasuresPlacebo4.7Standard Error 5.19percentage change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 900 mg-1.4Standard Error 4.65Percentage Change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 1500 mg-18.0Standard Error 4.70Percentage Change
Percentage Change From Baseline in Hemolysis MeasuresPlacebo6.8Standard Error 4.73Percentage Change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 900 mg1.6Standard Error 3.68Percentage Change
Percentage Change From Baseline in Hemolysis MeasuresVoxelotor 1500 mg-4.6Standard Error 3.69Percentage Change
Percentage Change From Baseline in Hemolysis MeasuresPlacebo3.0Standard Error 3.75Percentage Change

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03036813/results

API referenceFor AI assistants